Compounding Pharmacy Industry Responds to FDA Crackdown on GLP-1 Drugs
APC CEO Scott Brunner discusses the regulatory landscape for compounded GLP-1 receptor agonists amid increasing scrutiny and legal battles over compounded peptide drugs.
Industry News
55 stories across all digests
India Semaglutide Prices Expected to Drop 70% as 50+ Generics Enter Market
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
Inside the UK's Grey Market Peptide Boom: BPC-157 via Discord Groups
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
India Semaglutide Trademark Disputes: Dr. Reddy's Renames Drug After Court Concerns
Dr. Reddy's will rename its semaglutide drug from 'Olymviq' to 'Olymra' after Delhi High Court flagged similarity to Novo Nordisk's 'Ozempic'. Fierce competition in India's generic market.
Skeptic Magazine: Peptide Deregulation Could Be 'Biggest Medical Experiment in History'
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.
AstraZeneca Builds Phase II Obesity Pipeline Including Oral GLP-1 and Peptide Agents
AstraZeneca has oral GLP-1 agents (AZD5004), peptide therapies (AZD6234), and dual agonist combinations in its Phase II obesity pipeline.
CNN: The 'Wild, Wild West' of Viral Peptide Claims
Report examining viral social media claims about peptides promising DNA repair, nerve relief, and wound healing, referencing RFK Jr.'s Joe Rogan appearance supporting peptide access.
Men's Health UK: Men Injecting Peptides for Muscle and Recovery Face Real Risks
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Eli Lilly and Novo Nordisk Strike MFN Deals to Lower GLP-1 Prices
Both pharma giants reached most-favored-nation pricing agreements with the Trump Administration to reduce costs of tirzepatide and semaglutide for American consumers.
Sherwood News: Peptide Gold Rush as Deregulation Triggers Industry Scramble
Companies are rushing to upgrade from gray-market research-grade to medical-grade peptide standards to supply doctors' offices as deregulation approaches.
Pinnacle Medicines Closes $89M Series B for AI-Driven Oral Peptide Pipeline
Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.
Hims & Hers Now Offers Novo Nordisk's FDA-Approved GLP-1 Medications
Hims & Hers announced Novo Nordisk's approved GLP-1 medications including Wegovy injections/pills and Ozempic are now available through its platform at lower-than-retail rates.
CBS News: US Peptide Searches Hit 10.1 Million in January 2026
CBS warns that viral peptide claims on social media far outpace clinical evidence, with 60% of 10.1M monthly searches related to GLP-1 drugs and many trending peptides lacking FDA approval.
Novo Nordisk to Slash US List Prices ~50% for Wegovy, Ozempic, and Rybelsus in 2027
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.
Peptide Therapeutics Market to Reach $70.2 Billion by 2031 at 7.16% CAGR
Mordor Intelligence reports the global peptide therapeutics market valued at $49.68B in 2026, projected to reach $70.2B by 2031 driven by cancer, metabolic disorders, and oral delivery advances.
1 in 8 US Adults Now Taking a GLP-1 Drug
About 1 in 8 US adults now report taking a GLP-1 drug per KFF. Experts caution effects are larger and longer-lasting when combined with lifestyle changes.
Zealand Pharma Opens U.S. Research Hub in Cambridge, MA
Zealand Pharma announced a new Cambridge research hub combining 25+ years of peptide expertise with AI-driven drug discovery, expanding its obesity and metabolic health pipeline.